Rubedo posts early win in age-related skin disease

Experimental therapy cut precancerous skin lesions by 46%, offering a glimpse of how longevity science could reshape disease treatment. A longevity biotech may have found an easier way to tackle a common precancerous skin condition. Actinic keratosis (AK) is hardly a household term. Yet millions of …